Tuesday, 13 November 2018

Nov 13

Session 6:
Clinical stroke trials

08:30 - 09:30

Chairs: Hanne Christensen (DK) and Martin Köhrmann (DE)
Secretary: Konstantinos Kostulas (SE)

08:30 – 08:45
How do we increase the generalisability of future stroke trials especially as to women and the old?
Speaker: Hanne Christensen (DK)

08:45 – 09:00
Clinical end-point trials for prolonged cardiac monitoring in stroke: needed
Speaker: Martin Köhrmann (DE)

09:00 – 09:15
Clinical end-point trials for prolonged cardiac monitoring in stroke: needless
Speaker: Georgios Tsivgoulis (GR)

09:15 – 09:30
Presentation of Draft Consensus Statement & Discussion
Speaker: Secretary and Chairs

Short session 7:
Post-stroke dysphagia

09:30 - 09:50

Chair: Niaz Ahmed (SE)

09:30 – 09:45
Swallowing test and beyond
Speaker: Emilia Michou (UK)

09:45 – 09:50
Discussion


Coffee Break

09:55 - 10:25

Short session 8:
Post-stroke early mobilization

10:25 - 10:45

Chair: Niaz Ahmed (SE)

10:25 – 10:40
Should we avoid early mobilisation after AVERT?
Speaker: Katharina Sunnerhagen (SE)

10:40 – 10:45
Discussion

Session 9:
Oral anticoagulation and reversal agents after stroke

10:45 - 12:00

Chairs: Joji Kuramatsu (DE) and Thorsten Steiner (DE)
Secretary: Boris Keselman (SE)

10:45 – 11:00
Use of reversal agents for anticoagulation in the setting of acute stroke (ischemic stroke eligible to revascularization or intracerebral hemorrhage)
Speaker: Jan Purrucker (DE)

11:00 – 11:15
Reinitiation of antithrombotics after ICH
Speaker: Eleni Korompoki (UK)

11:15 – 11:30
Antithrombotic management in patients with atrial fibrillation and microbleeds
Speaker: Andreas Charidimou (UK/USA)

11:45 – 12:00
Presentation of Draft Consensus Statement & Discussion
Speaker: Secretary and Chairs


Lunch and Poster exhibition

12:00 - 13:00

Industry Symposium Boehringer Ingelheim:
Secondary stroke prevention in 2018 and beyond

12:00 - 13:00

Chair: Martin Grond

Setting the stage: a closer look at NO ACs for stroke
prevention
Speaker: Martin Grond, DE

Stroke prevention in AF: latest evidence with NO ACs
Speaker: Robin Lemmens, BE

Practical management of dabigatran and idarucizumab
in acute stroke
Speaker: Thorsten Steiner, DE

Cryptogenic stroke: where does embolic stroke of
undetermined source (ESUS) fit in?
Speaker: Martin Grond, DE

Panel discussion and Q&A Moderated by Martin Grond

Session 10:
IVT in acute ischaemic stroke

13:00 - 14:30

Chairs: Götz Thomalla (DE) and Robert Mikulik (CZ)
Secretary: Michael Mazya (SE)

13:00 – 13:15
Thrombolysis in minor stroke- No need for IVT in minor stroke
Speaker: Pooja Khatri (USA)

13:15 – 13:30
Thrombolysis in minor stroke: There is still good evidence to continue treating minor stroke with IVT
Speaker: William Whiteley (UK)

13:30 – 13:45
Criteria for identification of possible candidates for late IVT (Wake up or unknown time of onset)
Speaker: Götz Thomalla (DE)

13:45 – 14:00
Should tenecteplase replace alteplase in routine care?
Speaker: Eivind Berge (NO)

14:00 – 14:15
Presentation of Draft Consensus Statement & Discussion
Speaker: Secretary and Chairs

14:15 – 14:30
Discussion


Coffee Break

14:30 - 15:00

Session 11:
Mechanical thrombectomy

15:00 - 16:30

Chairs: Gary A. Ford (UK) and Joan Marti-Fabregas (ES)
Secretary: Åsa Kuntze Söderqvist (SE)

15:00 – 15:15
Intravenous thrombolysis before endovascular treatment: beneficial or just dangerous?
Speaker: Diederik W. J. Dippel (NL)

15:15 – 15:30
Thrombectomy beyond the conventional therapeutic window and in unwitnessed stroke
Speaker: Satu Mustanoja (FI)

15:30 – 15:45
Conscious sedation or general anaesthesia in patients undergoing endovascular procedures
Speaker: Mads Rasmussen (DK)

15:45 – 16:00
Critical review of the ESO-ESMINT guideline
Speaker: Gary A. Ford (UK)

16:00 – 16:15
Presentation of Draft Consensus Statement
Speaker: Secretary and Chairs

16:15 – 16:30
Discussion


Summary and closing of the meeting

16:30 - 16:45